Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

An ethics refresher for doctors in moral distress: theory and practice.

Martin LP.

Br J Hosp Med (Lond). 2019 Mar 2;80(3):C39-C41. doi: 10.12968/hmed.2019.80.3.C39. No abstract available.

PMID:
30860913
2.

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Birrer MJ, Betella I, Martin LP, Moore KN.

Oncologist. 2019 Apr;24(4):425-429. doi: 10.1634/theoncologist.2018-0459. Epub 2019 Jan 11. No abstract available.

PMID:
30635448
3.

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.

Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK.

Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.

PMID:
30413525
4.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.

PMID:
30347019
5.

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.

Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ.

Gynecol Oncol. 2018 Oct;151(1):46-52. doi: 10.1016/j.ygyno.2018.07.017. Epub 2018 Aug 6.

6.

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Burger RA, Deng W, Makker V, Collins Y, Gray H, Debernardo R, Martin LP, Aghajanian C.

Gynecol Oncol. 2018 Sep;150(3):466-470. doi: 10.1016/j.ygyno.2018.06.017. Epub 2018 Jul 3.

7.

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP.

Gynecol Oncol. 2018 Mar;148(3):507-514. doi: 10.1016/j.ygyno.2017.12.029. Epub 2018 Jan 17.

PMID:
29352572
8.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.

Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM.

JAMA Oncol. 2018 Jul 12;4(7):e173776. doi: 10.1001/jamaoncol.2017.3776. Epub 2018 Jul 12.

9.

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ.

Future Oncol. 2018 Jan;14(2):123-136. doi: 10.2217/fon-2017-0379. Epub 2017 Nov 3. Review.

10.

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

Meeker CR, Wong YN, Egleston BL, Hall MJ, Plimack ER, Martin LP, von Mehren M, Lewis BR, Geynisman DM.

J Natl Compr Canc Netw. 2017 Oct;15(10):1224-1233. doi: 10.6004/jnccn.2017.0161.

PMID:
28982748
11.

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.

Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):402-407. doi: 10.1016/j.ygyno.2017.08.015. Epub 2017 Aug 24.

12.

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J Jr.

Clin Cancer Res. 2017 Oct 1;23(19):5703-5710. doi: 10.1158/1078-0432.CCR-16-3261. Epub 2017 Jun 27.

13.

CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.

Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY.

Clin Cancer Res. 2017 Jul 15;23(14):3684-3691. doi: 10.1158/1078-0432.CCR-16-1859. Epub 2017 Feb 7.

14.

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.

J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28.

15.

Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN.

J Oncol Pract. 2016 Jul;12(7):e755-64. doi: 10.1200/JOP.2016.011049. Epub 2016 Jun 21.

16.

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C.

J Clin Oncol. 2016 Jul 1;34(19):2279-86. doi: 10.1200/JCO.2015.65.8153. Epub 2016 May 23.

17.

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ.

N Engl J Med. 2016 Feb 25;374(8):738-48. doi: 10.1056/NEJMoa1505067.

18.

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.

Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA.

Mol Cancer Ther. 2015 Nov;14(11):2569-75. doi: 10.1158/1535-7163.MCT-15-0475. Epub 2015 Sep 2.

19.

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.

Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S.

Gynecol Oncol. 2015 Feb;136(2):246-53. doi: 10.1016/j.ygyno.2014.12.019. Epub 2014 Dec 17.

PMID:
25528496
20.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE.

Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7.

21.

Phase II trial of vorinostat in advanced melanoma.

Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A.

Invest New Drugs. 2014 Jun;32(3):526-34. doi: 10.1007/s10637-014-0066-9. Epub 2014 Jan 25.

PMID:
24464266
22.

Transfusion Requirements in Microsurgical Reconstruction in Maxillofacial Surgery: Ethical and Legal Problems of Patients Who Are Jehovah's Witnesses.

Martin LP, Arias-Gallo J, Perez-Chrzanowska H, Seco PR, Moro JG, Burgueño-Garcia M.

Craniomaxillofac Trauma Reconstr. 2013 Mar;6(1):31-6. doi: 10.1055/s-0033-1333828. Epub 2013 Jan 24.

23.

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ.

Gynecol Oncol. 2014 Mar;132(3):526-30. doi: 10.1016/j.ygyno.2013.12.018. Epub 2013 Dec 18.

24.

Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC.

Clin Cancer Res. 2013 Sep 15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115. Epub 2013 Jul 30.

25.

Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer.

Martin LP, Krasner C, Rutledge T, Ibañes ML, Fernández-García EM, Kahatt C, Gómez MS, McMeekin S.

Med Oncol. 2013;30(3):627. doi: 10.1007/s12032-013-0627-3. Epub 2013 Jun 15.

PMID:
23771800
26.

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.

Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB.

Br J Cancer. 2012 Oct 9;107(8):1268-76. doi: 10.1038/bjc.2012.407. Epub 2012 Sep 20.

27.

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.

Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB.

Br J Cancer. 2012 Oct 9;107(8):1277-85. doi: 10.1038/bjc.2012.406. Epub 2012 Sep 18.

28.

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.

Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM.

Gynecol Oncol. 2012 Dec;127(3):451-5. doi: 10.1016/j.ygyno.2012.09.008. Epub 2012 Sep 14.

29.

Atypical case of congenital maxillomandibular fusion with duplication of the craniofacial midline.

Martín LP, Pérez MM, García EG, Martín-Moro JG, González JI, García MB.

Craniomaxillofac Trauma Reconstr. 2011 Jun;4(2):113-20. doi: 10.1055/s-0031-1279674.

30.

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM.

Gynecol Oncol. 2012 Apr;125(1):136-40. doi: 10.1016/j.ygyno.2011.11.042. Epub 2011 Dec 2.

31.

Mandibular osteoradionecrosis: use of sequential fibula free flaps for a remote sequence of complications.

Martín LP, Gallo LJ, Pons MC, Soto MJ, Carretero JL, García MB.

Craniomaxillofac Trauma Reconstr. 2010 Jun;3(2):91-5. doi: 10.1055/s-0030-1254380.

32.

Effects of oropharyngeal air-pulse stimulation on swallowing in healthy older adults.

Theurer JA, Czachorowski KA, Martin LP, Martin RE.

Dysphagia. 2009 Sep;24(3):302-13. doi: 10.1007/s00455-009-9207-2. Epub 2009 Apr 24.

PMID:
19390893
33.

Management of recurrent ovarian carcinoma: current status and future directions.

Martin LP, Schilder RJ.

Semin Oncol. 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. Review.

PMID:
19332246
34.

Platinum resistance: the role of DNA repair pathways.

Martin LP, Hamilton TC, Schilder RJ.

Clin Cancer Res. 2008 Mar 1;14(5):1291-5. doi: 10.1158/1078-0432.CCR-07-2238. Review.

35.

Abnormal bone and mineral metabolism in kidney transplant patients--a review.

Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K.

Am J Nephrol. 2008;28(2):246-53. Epub 2007 Nov 7. Review.

36.
37.

Elongation behavior of calcaneofibular and cervical ligaments in a closed kinetic chain: pathomechanics of lateral hindfoot instability.

Martin LP, Wayne JS, Owen JR, Smith RT, Martin SN, Adelaar RS.

Foot Ankle Int. 2002 Jun;23(6):515-20.

PMID:
12095120
38.

Experimental and simulated ultrasonic characterization of complex damage in fused silica.

Martin LP, Chambers DH, Thomas GH.

IEEE Trans Ultrason Ferroelectr Freq Control. 2002 Feb;49(2):255-65.

PMID:
11885682
39.
40.

Implementing a critical pathway for oral rehydration of mild to moderate dehydration of children.

Martin LP.

J Emerg Nurs. 2001 Dec;27(6):597-601. No abstract available.

PMID:
11712018
41.

Electrophysiological comparison of 5-Hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing.

Martin LP, Jackson DM, Wallsten C, Waszczak BL.

J Pharmacol Exp Ther. 1999 Feb;288(2):820-6.

PMID:
9918594
42.

Expression of a dopamine D2 receptor-activated K+ channel on identified striatopallidal and striatonigral neurons.

Waszczak BL, Martin LP, Greif GJ, Freedman JE.

Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11440-4.

43.

Elongation behavior of calcaneofibular and cervical ligaments during inversion loads applied in an open kinetic chain.

Martin LP, Wayne JS, Monahan TJ, Adelaar RS.

Foot Ankle Int. 1998 Apr;19(4):232-9.

PMID:
9578103
44.

Care questioned.

Martin LP.

J Am Dent Assoc. 1998 Apr;129(4):410, 412. No abstract available.

PMID:
9573692
45.
46.
47.
49.

Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.

Jackson DM, Martin LP, Larsson LG, Cox RF, Waszczak BL, Ross SB.

Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):290-9.

PMID:
2126347
50.

Supplemental Content

Loading ...
Support Center